Molecularly targeted agents are increasingly utilized to treat cancer. Unfortunately, biomarkers to guide this therapy are infrequently applied to FNA samples.
No takes yet. Share an insight, caveat, or question.
Douglas P. Clark (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: